NCT05446428View on ClinicalTrials.gov

Evaluation of Type I IFN Level and Disease Activity in SLE Patients

UnknownOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

July 31, 2024

Conditions
Elevated Level of IFN Type I in SLE Patients
Interventions
OTHER

study of IFNGS expression biomarkers

Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

V.A. Nasonova Research Institute of Rheumatology, Moscow

OTHER